SPOTLIGHT -
FDA approves generic valsartan to mitigate shortages
FDA clears subcutaneous injectable to treat breast cancer
Breakthrough nasal spray for depression not without risks
Nasal spray offers promise for treatment-resistant depression, but proceed with caution.
HHS names FDA acting chief as Gottlieb resignation sparks worries
How FDA Chief Gottlieb’s resignation could impact the pharma industry.
Eli Lilly launches generic insulin ahead of Congressional hearings
Blood pressure drug recalls soar
The recalls of a widely used hypertension blood drug due to carcinogenic impurities are expanding.
Rheumatoid arthritis drug poses fatal side effects
FDA is warning about an increased risk of death and blood clots in the lungs in patients with rheumatoid arthritis taking a specific dosage of this drug.
Startling number of patients inappropriately prescribed fentanyl
Many patients who were prescribed fentanyl should not have received the drug, a new study said.
FDA: Higher death risk with this gout drug
FDA is requiring the addition of a Black Box Warning to a gout drug that has an increased risk of death.
FDA clears novel diabetes, tropical disease therapies
FDA approved first interoperable insulin pump, as well as the only FDA-approved drug for patients with a neglected tropical disease.
Inside Trump’s plan to lower drug prices
In his recent State of the Union address, President Trump promised to continue lowering drug prices and fund research for HIV/AIDS and childhood cancer. Here are the ways experts say he will implement those pledges.
FDA cracks down on fake Alzheimer’s products
FDA warns companies illegally selling drugs and dietary supplements claiming to cure Alzheimer’s and other conditions.
Pharma maker expands ibuprofen recall
Generic asthma inhaler gets FDA nod
FDA approved the first generic of a popular inhaler to treat asthma and chronic obstructive pulmonary disease
Large PBM covers 2 migraine treatments, excludes another
CVS Health adds new migraine drugs to its list of covered drugs, but excludes one rival treatment.
FDA approves cabozantinib for treatment-experienced patients with aggressive liver cancer
FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.
The impact of high drug prices on hospitals
A new report details the financial strain rising drug prices are having on patients and hospitals alike.
First generic tablet version of popular epilepsy drug approved
FDA cleared the first generic tablet version of a top-selling epilepsy drug.
New bills aim to lower drug prices
New legislation designed to curb drug costs comes on the heels of many pharma makers raising prices this year as well as payers saying they expect higher drug acquisition costs.
FDA clears record number of drugs
FDA approved a record number of novel treatments in 2018.
Blood pressure drug recall expands
Soon after FDA warned the manufacturer involved in a massive nationwide recall of valsartan- and losartan-containing drugs, the recall is expanding. Find out why.
Novel pair of therapies offers hope to patients with rare blood disorders
Two new therapies approved by FDA signal significant advancement in treating rare blood diseases.
Pharma makers to hike drug prices in 2019
FDA issues warning on antibiotics class
Fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the aorta, FDA said in a new warning.
FDA approves Tecentriq, Avastin combo for first-line treatment of lung cancer
A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.
FDA warns maker of ingredient in huge heart drug recall
After an expanded recall of the blood pressure medication valsartan, FDA is warning the manufacturer of the carcinogenic ingredient involved.
Pharma makers recall 2 important drugs
Two major drug recalls in the last week include an expanded recall of a widely used blood pressure medication as well as over-the-counter infant ibuprofen.
The impact of Medicare Part D proposals on drug pricing
Find out how healthcare organizations and analysts feel about new Medicare Part D proposals and drug pricing.
FDA approves first biosimilar to Rituxan
FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.
Rheumatoid arthritis drug snags expanded indication
FDA approved an autoinjector to treat rheumatoid arthritis and other diseases.